CARTD-BG-1: First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma
Study Details
Study Description
Brief Summary
ths study consist in testing a CAR T therapy (ARI0003 cells (antiCD19 and antiBCMA) in patients suffering relapsed NHL (that means that symptoms of NHL reappeared ) or refractory (that means that they did not respond to other treatments). This is a first in human study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Early Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: ARI0003 ARI0003 will be administered intravenously under a split regime. A total dose between 0.5 and 5 x106 cell/Kg will be administered in 3 administrations (fractions): |
Genetic: ARI0003
Treatment with ARI0003 cells
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Rate of > grade 3 CRS and/or ICANS [in the first 30 days after ARI0003 administration]
Rate of patients who develop grade > 3 cytokine release syndrome (CRS) and/or grade > 3 immune cell associated neurotoxicity syndrome (ICANS) according to the criteria and grading defined in the international consensus document of the American Society for Transplantation and Cellular Therapy (ASTCT criteria). ASTCT score can be between 1 and 4 (being 1 the minimum value and 4 the maximum) and where higher score means worse outcome.
- ORR [within 3 months post ARI0003 infusion]
Overall response rate (ORR) according to Lugano criteria (best response within 3 months post ARI0003 infusion
Secondary Outcome Measures
- Procedure-related mortality (PRM) [through study completion, an average of 24 months]
Procedure-related mortality (PRM), defined as any death not directly cause by the lymphoma that is related with the procedure. For the estimation of PRM, disease relapse will be considered as a competing event
- Toxicity: incidence of AE [at 3 and 12 months]
Toxicity defined as the incidence of grade >3 adverse events (AEs) as per CTCAE version 5.0. The following AEs will be considered AEs of special interest (AESI): CRS, ICANS, macrophagic activation syndrome (MAS), tumour lysis syndrome (TLS), prolonged cytopenia (beyond 6 months), infections and second primary malignancies
- Complete response rate [at 3 months]
Complete response rate
- Duration of response, [from month 3 to study completion, an average of 24 months]
Duration of response, calculated from the time of first disease evaluation (3 months);
- Progression-free survival [through study completion, an average of 24 months]
Progression-free survival, calculated from ARI-0003 cell infusion
- Overall survival [through study completion, an average of 24 months]
Overall survival, calculated from ARI-0003 cell infusion
Eligibility Criteria
Criteria
Inclusion Criteria:
-
- Diagnosis of CD19+ or CD269+ relapsed/refractory (R/R) aggressive B-cell lymphoma in one of the following circumstances:
-
Burkitt's lymphoma;
-
Histology not covered by approved CART19-cell products (plasmablastic lymphoma, primary effusion lymphoma, intravascular lymphoma, transformed lymphoma from marginal zone lymphoma or chronic lymphocytic leukaemia, primary cutaneous DLBCL, T-cell rich DLBCL, high-grade B-cell lymphoma, grey zone lymphoma or grade 3b follicular lymphoma); or
-
Aggressive B-cell lymphoma that is refractory or relapsing after treatment with CART19-cell therapy.
- Age older than 18 years. 3. ECOG performance status of 0-2. 4. Estimated life expectancy of at least 3 months. 5. Adequate venous access and absence of contraindications for lymphapheresis. 6. Signature of informed consent. 7. In patients who have received any anti-CD19 or anti-CD269 therapy (e.g. tisagenlecleucel, axicabtagene autoleucel, tafasitamab, loncastuximab, belantamab mafodotin, idecabtagene vicleucel, etc.), a centralised tumour sample confirming the expression of at least one of the antigens (either CD19 or CD269) will be needed at study inclusion
Exclusion Criteria:
-
- Any experimental or non-commercialized therapy in the previous 4 weeks. 2. Any other concomitant neoplasia, unless it has been in complete remission for 3 years or longer, except for non-melanoma skin cancer or completely resected in situ carcinoma.
-
Active immunosuppressive therapy except for prednisone 10 mg/day (or equivalent).
-
Active infection requiring systemic medical therapy. 5. Active HBV or HCV infection. 6. Positive serology for HIV. 7. Any concomitant and uncontrolled medical disease. 8. Severe organic impairment defined by cardiac ejection fraction <40%, DLCO <40%, GFR <30 ml/min or bilirubin >3 times the upper limit of normality (unless due to Gilbert's syndrome).
-
Lactating or pregnant women. 10. Men or women of childbearing potential unable or unwilling to use highly efficient contraceptive measures from the beginning until the end of the study.
-
CNS disease in the form of a macroscopic solid lesion in the encephalon or spinal cord (isolated meningeal disease is allowed
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU Santiago de Compostela | Santiago De Compostela | A Coruña | Spain | |
| 2 | Hospital Clínic Barcelona | Barcelona | Spain | 08036 | |
| 3 | H. Ramon y Cajal | Madrid | Spain | ||
| 4 | H.U. Virgen de la Arrixaca | Murcia | Spain | ||
| 5 | Hospital Central de Asturias | Oviedo | Spain | ||
| 6 | Hospital Son Espases | Palma De Mallorca | Spain | ||
| 7 | H. Clínico de Salamanca | Salamanca | Spain |
Sponsors and Collaborators
- Fundacion Clinic per a la Recerca Biomédica
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CARTD-BG-1
- 2023-5072-13-97-00